The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Abstract
Purpose: Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population. Patients and Methods: Panobinostat 40 mg was administered orally three times per week. The primary end point was objective response rate (ORR) based on investigator assessment of radiologic imaging. Secondary end points included ORR by independent central review, time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival, and safety. Exploratory biomarker analyses were performed. Results: The 129 treated patients (median age, 32 years; range, 18 to 75 years) were heavily pretreated with a median of four (range, two to seven) prior systemic regimens, and 41% did not respond to the regimen immediately preceding panobinostat. Tumor reductions occurred in 96 patients (74%). Objective response was achieved by 35 patients (27%), including 30 (23%) partial responses and five (4%) complete responses. The median TTR was 2.3 months, median DOR was 6.9 months, and median PFS was 6.1 months. The estimated 1-year overall survival rate was 78%. Common nonhematologic adverse events (AEs)—diarrhea, nausea, vomiting, and fatigue—were generally grade 1 and 2. Most common grade 3 and 4 hematologic AEs—thrombocytopenia, anemia, and neutropenia—were manageable. Early reductions in thymus and activation-regulated chemokine were observed in patients achieving complete or partial response. Conclusion: In the largest, prospective, multicenter, international trial conducted in heavily pretreated patients with HL who relapsed or were refractory to ASCT, panobinostat monotherapy demonstrated antitumor activity, resulting in durable responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P., Kirchner, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08938-9 · Cited by 1,140
Linch, D. C., Goldstone, A. H., McMillan, A., Chopra, R., Vaughan Hudson, G., Winfield, D., Hancock, B., Moir, D., & Milligan, D. (1993) · The Lancet · doi:10.1016/0140-6736(93)92411-l · Cited by 1,051
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Engert, A., André, M., Federico, M., Illidge, T., Hutchings, M., & Ladetto, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu181 · Cited by 474
Self-citationDevelopment of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Dickinson, M. J., Johnstone, R. W., & Prince, H. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9596-y · Cited by 148
Self-citationBishton, M. J., Harrison, S. J., Martin, B. P., McLaughlin, N. M., James, C., Josefsson, E. C., Henley, K. J., Kile, B. T., Prince, H. M., & Johnstone, R. W. (2011) · Blood · doi:10.1182/blood-2010-11-318055 · Cited by 142
Self-citationPrince, H. M., Bishton, M. J., & Johnstone, R. W. (2009) · Future Oncology · doi:10.2217/fon.09.36 · Cited by 131
Self-citationSerum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
Niens, M., Visser, L., Nolte, I. M., van der Steege, G., Diepstra, A., Cordano, P., Jarrett, R. F., Meerman, G. J. T., Poppema, S., & van den Berg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06964.x · Cited by 129
Cited by
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Self-citationHistone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Metadata
- Authors
- Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P., Gallagher, J., Le Corre, C., Shen, A., & Engert, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-06-20
- Volume
- 30
- Issue
- 18
- Pages
- 2197-2203
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168713493
- Cited by
- 263
- References
- 18
- FWCI
- 25.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. https://app.cochat.ai/papers/10.1200/jco.2011.38.1350
- The paper
- Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P., Gallagher, J., Le Corre, C., Shen, A., & Engert, A. (2012). Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.38.1350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.